JP2024500858A5 - - Google Patents
Info
- Publication number
- JP2024500858A5 JP2024500858A5 JP2023537689A JP2023537689A JP2024500858A5 JP 2024500858 A5 JP2024500858 A5 JP 2024500858A5 JP 2023537689 A JP2023537689 A JP 2023537689A JP 2023537689 A JP2023537689 A JP 2023537689A JP 2024500858 A5 JP2024500858 A5 JP 2024500858A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130095P | 2020-12-23 | 2020-12-23 | |
| US63/130,095 | 2020-12-23 | ||
| US202163250996P | 2021-09-30 | 2021-09-30 | |
| US63/250,996 | 2021-09-30 | ||
| US202163254970P | 2021-10-12 | 2021-10-12 | |
| US63/254,970 | 2021-10-12 | ||
| US202163288492P | 2021-12-10 | 2021-12-10 | |
| US63/288,492 | 2021-12-10 | ||
| PCT/US2021/064930 WO2022140586A2 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for reducing hla-a in a cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500858A JP2024500858A (ja) | 2024-01-10 |
| JPWO2022140586A5 JPWO2022140586A5 (https=) | 2025-07-08 |
| JP2024500858A5 true JP2024500858A5 (https=) | 2025-07-08 |
Family
ID=81212453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537689A Pending JP2024500858A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｈｌａ－ａを低減するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024478A1 (https=) |
| EP (1) | EP4267724A2 (https=) |
| JP (1) | JP2024500858A (https=) |
| KR (1) | KR20230124664A (https=) |
| AU (1) | AU2021409732A1 (https=) |
| CA (1) | CA3206284A1 (https=) |
| CL (2) | CL2023001860A1 (https=) |
| CO (1) | CO2023009612A2 (https=) |
| CR (1) | CR20230320A (https=) |
| IL (1) | IL303971A (https=) |
| MX (1) | MX2023007466A (https=) |
| TW (1) | TW202239959A (https=) |
| WO (1) | WO2022140586A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3228879A1 (en) * | 2021-08-16 | 2023-02-23 | Beam Therapeutics Inc. | Persistent allogeneic modified immune cells and methods of use thereof |
| EP4599046A1 (en) * | 2022-10-05 | 2025-08-13 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| AU2024324870A1 (en) | 2023-08-14 | 2026-02-12 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202521564A (zh) | 2023-08-14 | 2025-06-01 | 美商英特利亞醫療公司 | 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3134515B1 (en) * | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| AU2017374044B2 (en) | 2016-12-08 | 2023-11-30 | Intellia Therapeutics, Inc. | Modified guide RNAs |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| EP3754018A4 (en) * | 2018-02-16 | 2021-11-24 | Kyoto University | LOW ANTIGENIC CELL PRODUCTION PROCESS |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| WO2019237069A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| BR112021007123A2 (pt) | 2018-10-15 | 2021-08-10 | University Of Massachusetts | edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase |
| JP2022512703A (ja) | 2018-10-16 | 2022-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のための組成物および方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| GB2596660B (en) * | 2019-01-07 | 2023-09-13 | Crisp Hr Therapeutics Inc | A non-toxic Cas9 enzyme and application thereof |
| KR20230017783A (ko) * | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
-
2021
- 2021-12-22 AU AU2021409732A patent/AU2021409732A1/en active Pending
- 2021-12-22 IL IL303971A patent/IL303971A/en unknown
- 2021-12-22 TW TW110148217A patent/TW202239959A/zh unknown
- 2021-12-22 EP EP21856911.9A patent/EP4267724A2/en active Pending
- 2021-12-22 CR CR20230320A patent/CR20230320A/es unknown
- 2021-12-22 CA CA3206284A patent/CA3206284A1/en active Pending
- 2021-12-22 MX MX2023007466A patent/MX2023007466A/es unknown
- 2021-12-22 KR KR1020237024853A patent/KR20230124664A/ko active Pending
- 2021-12-22 WO PCT/US2021/064930 patent/WO2022140586A2/en not_active Ceased
- 2021-12-22 JP JP2023537689A patent/JP2024500858A/ja active Pending
-
2023
- 2023-06-20 CL CL2023001860A patent/CL2023001860A1/es unknown
- 2023-06-22 US US18/339,665 patent/US20240024478A1/en active Pending
- 2023-07-19 CO CONC2023/0009612A patent/CO2023009612A2/es unknown
- 2023-10-17 CL CL2023003086A patent/CL2023003086A1/es unknown